Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line
oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or …

Purpose Colorectal cancer is the second leading cause of cancer mortality in the United
States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves …

Background Bevacizumab significantly improves survival when added to chemotherapy for
metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) …

Purpose To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine
regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal …

Background This systematic review and meta-analysis aims to evaluate the additive effect of
bevacizumab when combined with first-line chemotherapy in metastatic colorectal cancer …

The BEBYP trial is a prospective, randomized, open-label, multicenter, phase III study
evaluating the continuation or reintroduction of bevacizumab with second-line …

Purpose. This analysis pooled individual patient data from randomized controlled trials
(RCTs) to more thoroughly examine clinical outcomes when adding bevacizumab to …

Background We report the results from a first-line phase III randomized clinical trial on
metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding …

3515 Background: Bevacizumab (Bev) added to IFL combination chemotherapy improves
survival in mCRC. This randomized study assesses the safety & tolerability of each of three …

Purpose Bevacizumab has demonstrated survival benefit in metastatic colorectal cancer
(mCRC) patients when combined with chemotherapy. Several randomized clinical studies …